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Abstract
Introduction: We have previously reported that induction of epidermal growth factor receptor and ErbB2 in response
to antihormonal agents may provide an early mechanism to allow breast cancer cells to evade the growth-inhibitory
action of such therapies and ultimately drive resistant cell growth. More recently, the other two members of the ErbB
receptor family, ErbB3 and ErbB4, have been implicated in antihormone resistance in breast cancer. In the present
study, we have investigated whether induction of ErbB3 and/or ErbB4 may provide an alternative resistance mechanism
to antihormonal action in a panel of four oestrogen receptor (ER)-positive breast cancer cell lines.
Methods: MCF-7, T47D, BT474 and MDAMB361 cell lines were exposed to fulvestrant (100 nM) for seven days, and
effects on ErbB3/4 expression and signalling, as well as on cell growth, were assessed. Effects of heregulin b1
(HRGb1) were also examined in the absence and presence of fulvestrant to determine the impact of ER blockade
on the capacity of this ErbB3/4 ligand to promote signalling and cell proliferation.
Results: Fulvestrant potently reduced ER expression and transcriptional activity and significantly inhibited growth
in MCF-7, T47D, BT474 and MDAMB361 cells. However, alongside this inhibitory activity, fulvestrant also consistently
induced protein expression and activity of ErbB3 in MCF-7 and T47D cells and ErbB4 in BT474 and MDAMB361 cell
lines. Consequently, fulvestrant treatment sensitised all cell lines to the actions of the ErbB3/4 ligand HRGb1 with
enhanced ErbB3/4-driven signalling activity, reexpression of cyclin D1 and significant increases in cell proliferation
being observed when compared to untreated cells. Indeed, in T47D and MDAMB361 HRGb1 was converted from a
ligand having negligible or suppressive growth activity into one that potently promoted cell proliferation.
Consequently, fulvestrant-mediated growth inhibition was completely overridden by HRGb1 in all four cell lines.
Conclusions: These findings suggest that although antihormones such as fulvestrant may have potent acute
growth-inhibitory activity in ER-positive breast cancer cells, their ability to induce and sensitise cells to growth
factors may serve to reduce and ultimately limit their inhibitory activity.
Introduction
The ability of antihormones to inhibit growth of oestro-
gen receptor (ER)-positive breast cancer cells has princi-
pally been attributed to the ability of these agents to
block the transcriptional activity of the ER and prevent
activation of genes responsible for mediating cell cycle
progression, such as cyclin D1 and c-Myc [1]. However,
more recent findings have demonstrated that the major-
ity of oestrogen (E2)-regulated genes in human breast
cancer cells are repressed rather than activated and that
many of these genes act as growth and/or transcriptional
repressors [2]. Thus, antihormones may exert their anti-
proliferative activity not only through suppression of
growth-promoting genes but also through an ability to
induce negative regulators of cell proliferation. Although
such an inductive mechanism will undoubtedly enhance
the growth inhibitory activity of antihormones in ER-
positive breast cancer, there is now evidence that this
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also been demonstrated that E2 can suppress, and anti-
hormones can induce, genes that promote cell prolifera-
tion and survival [3-5].
Two key proproliferative survival genes that have been
established as E2-suppressed antihormone-induced genes
in a range of ER-positive breast cancer cell lines are the
ErbB receptors epidermal growth factor receptor (EGFR)
and ErbB2 [2-4,6-11]. As there is considerable preclinical
and clinical evidence that both EGFR and ErbB2 play a
central role in driving acquisition of antihormone resis-
tance in breast cancer [12-19], it is possible that antihor-
mones may actually play an active role in limiting their
own activity through an ability to promote expression of
these potent growth promoters. Indeed, there is now evi-
dence based on in vitro and in vivo MCF-7 cell models of
ER-positive breast cancer that increased expression of
EGFR and ErbB2 is an early response to tamoxifen treat-
ment and that this induction of ErbB signalling maintains
residual activity of key downstream signalling pathways,
such as the mitogen-activated protein kinase (MAPK)
and phosphatidylinositol 3-kinase (PI3K) cascades
[10,13]. Such signalling may allow cells to evade inhibi-
tion during the drug-responsive phase, as targeting these
ErbB receptors in combination with tamoxifen sup-
presses the residual signalling activity and greatly
improves and extends the growth-inhibitory action of
this antihormone in the two cell models [10,13]. Similar
preclinical findings have also been reported for the pure
anti-ER fulvestrant [10], and recent clinical studies exam-
ining cotargeting ER and EGFR and/or ErbB2 signalling
pathways have reported improved response to a range of
endocrine therapies in breast cancer patients [20,21].
Despite these positive findings in clinical trials, it should
also be noted that a considerable number of patients do
not benefit from such combination treatments, suggest-
ing that alternative EGFR- and ErbB2-independent
mechanisms of resistance to antihormones are active in
the clinical setting [20].
Microarray studies have now revealed a vast range of
E2-suppressed, antihormone-induced genes in addition
to EGFR and ErbB2, which may also play a significant
role in modulating response and resistance to endocrine
therapies [2-5]. These genes include ErbB3 and ErbB4,
the remaining members of the ErbB receptor family,
which are receptors for the neuregulin (NRG) family of
growth factors: NRG1 or heregulin (HRG), NRG2,
NRG3 and NRG4 [2,22-24]. Like EGFR and ErbB2,
ErbB4 can form active homodimers; however, ErbB3 is
catalytically inactive and thus requires heterodimeriza-
tion with another ErbB family member to promote sig-
nalling [25]. Both ErbB3 and ErbB4 have been shown to
be E2-suppressed and tamoxifen-induced in ER-positive
breast cancer cells, suggesting a potential role for both
receptors in antihormone response and resistance [2,22].
This is supported by the findings of Tang and colleagues
[26], who demonstrated that inoculation of HRG-trans-
fected MCF-7 cells into the mammary fat pads of ovar-
iectomised, athymic nude mice can generate oestrogen-
independent and anti-oestrogen-resistant tumours. More
recently, the weight of evidence has supported a role for
ErbB3, rather than ErbB4, with increased activation of
ErbB3 being reported in acquired tamoxifen- and fulves-
trant-resistant MCF-7 cells [27,28] and its downregula-
tion-enhancing responsiveness of ErbB2-overexpressing,
de novo antihormone-resistant breast cancer cells to
tamoxifen [29]. Moreover, ErbB1-ErbB3 overexpression
has been reported to predict early relapse during tamox-
ifen therapy in ER-positive breast cancer patients
[30,31]. The involvement of ErbB4 remains unclear, as
in acquired tamoxifen-resistant MCF-7 cells expression
of this receptor is enhanced [28], whereas in a panel of
fulvestrant-resistant MCF-7 cells it is decreased [27].
Furthermore, in agreement with the fulvestrant resis-
tance studies, loss of ErbB4 expression has been
reported to be an independent marker of tamoxifen
resistance in patients with primary breast cancer [32].
In the present study, we have examined the acute
inductive capacity of the pure anti-ER fulvestrant on
ErbB3 and ErbB4 receptor expression in a panel of four
ER-positive breast cancer cell lines, two ErbB2-negative
(MCF-7 and T47D) and two ErbB2-positive (BT474 and
MDAMB361), and assessed the effect of ligand activa-
tion of these receptors on antihormone response. We
demonstrate that seven-day fulvestrant treatment
induces the expression of both the ErbB3 and ErbB4
receptors, resulting in enhanced sensitivity to the action
of HRGb1 and enabling this ligand to readily promote
fulvestrant-resistant cell growth in all four cell lines.
Materials and methods
Cell culture
All tissue culture media and constituents were pur-
chased from Gibco Europe Ltd. (Paisley, UK), and tissue
culture plastics were obtained from Nunc (Roskilde,
Denmark). A panel of four ER-positive breast cancer cell
lines were used in this study: MCF-7, T47D, BT474 and
MDAMB361. All of these cell lines were maintained in
phenol red-free RPMI (wRPMI) medium containing 5%
foetal calf serum (FCS), penicillin-streptomycin (10 IU/
ml to 10 μg/ml), Fungizone (2.5 μg/ml), glutamine (4
mM) at 37°C in a humidified 5% CO2 atmosphere.
Western blot analysis and reverse transcriptase
polymerase chain reaction assay
Experimental cell culture
The four cell lines were grown in wRPMI supplemented
with 5% FCS for seven days in the presence of fulvestrant
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Further studies were also performed where cell lines
w e r eg r o w ni nw R P M Is u p p l e m e n t e dw i t h5 %F C Sf o r
seven days in either the absence or the presence of ful-
vestrant (100 nM) and subsequently exposed to either
HRGb1 (0.1 to 10 ng/ml in ethanol; Sigma, Poole, UK) or
vehicle control for five minutes. All experiments were
performed at least three times.
Protein cell lysis
Cells were washed three times with phosphate-buffered
saline (PBS) and lysed using ice-cold lysis buffer (for
composition used, see [12]). The cellular contents were
transferred to microfuge tubes and clarified by centrifu-
gation at 13,000 rpm for 15 minutes at 4°C, and super-
natant aliquots were stored at -20°C until required.
Total protein concentrations were determined using the
DC Bio-Rad protein assay kit (Bio-Rad Laboratories
Ltd., Hemel Hempstead, UK).
Western blot analysis
Protein samples from total cell lysates (50 μg) were sub-
jected to electrophoretic separation on a 7.5% polyacry-
lamide gel and transblotted onto a nitrocellulose
membrane (Schleicher and Schuell, Dassel, Germany).
Blots were blocked at room temperature for one hour in
5% skimmed milk powder made up in Tris-buffered sal-
ine (TBS)-Tween 20 (TBS-T) (0.05%) and incubated for
a minimum of one hour in primary antibody diluted
1:40,000 for b-actin (reference control) or 1:1,000 for
epidermal growth factor receptor (EGFR), ErbB2, ErbB3,
ErbB4, AKT, extracellular signal-regulated kinases 1 and
2 (ERK1/2), MAPK, protein kinase C and cyclin D1 in
1% MARVEL/TBS-T. The membranes were washed
three times in TBS-T and then incubated for one hour
with the required secondary immunoglobulin G horse-
radish peroxidase-labelled donkey anti-rabbit or sheep
anti-mouse antibody (Amersham Biosciences UK Ltd.,
Buckinghamshire, UK), diluted 1:20,000 in 1% MAR-
VEL/TBS-T. Detection was performed using West Dura
chemiluminescence detection reagents (Pierce and War-
riner Ltd., Chester, UK). Antibodies used were total
EGFR (SC-03), ErbB2 (SC-284), ErbB3 (SC-285), ErbB4
(SC-283), phospho-ErbB4 (pY1056, SC-33040) and
cyclin D1 (SC20044; Insight Biotechnology Ltd., Wemb-
ley, UK), as well as phospho-ErbB3 (pY1289, 4791),
phospho-ErbB4 (pY1248, 4757), phospho-ErbB2
(pY1248, 2247), phospho-EGFR (pY1068, 2234), total
AKT (9272), phospho-AKT (pS473, 9271), total ERK1/2
(9102) and phospho-ERK1/2 (pT202/pY204, 9101) (New
England Biolabs, Hertfordshire, UK), ERa (ID-5) (Dako,
Ely, UK) and b-actin (AC-15) (Sigma). These antibodies
were selected as they have been demonstrated to be
monospecific and do not cross-react with other family
members.
Reverse transcriptase polymerase chain reaction
Total RNA was isolated from the four cell lines using an
RNA isolator kit (TRI Reagent; Sigma), and 1 μgw a s
reverse-transcribed using standard conditions as
described previously [12]. The resultant cDNA samples
were amplified using specific primers for progesterone
receptor (PgR) and b-actin (housekeeping positive con-
trol), respectively, and conditions were optimised as
described previously [12]. Briefly, an initial denaturing
step of 95°C for two minutes was followed by a set
number of cycles of 94°C for 30 seconds, 55°C for 30
seconds and 72°C for 30 seconds. PCR products were
separated on a 3% wt/vol agarose gel containing ethi-
dium bromide and visualised by ultraviolet illumination.
The primers used for ErbB3, ErbB4, PgR and b-actin
were reported previously [12].
Cell proliferation
Cell monolayers were grown for 7 days in wRPMI sup-
plemented with 5% FCS in the presence of either fulves-
trant (100 nM), fulvestrant and gefitinib (1 µM; a kind
gift from AstraZeneca, Macclesfield), fulvestrant and
trastuzumab (100 nM; a kind gift from Roche Diagnos-
tics, Penzburg), HRGb1 (10 ng/ml), a combination of
these agents or the appropriate vehicle control. Cell
population growth was then evaluated by means of tryp-
sin dispersion of the cell monolayers and cell number
was measured using a Coulterc o u n t e r( L u t o n ,U K ) .A l l
experiments were performed in triplicate.
Immunocytochemistry
Experimental cell culture
The 4 cell lines were grown on sterile 3-aminopropyl-
triethoxysilane-coated coverslips at 1 × 10
4 cells/cm
2 in
wRPMI supplemented with 5% FCS for 7 days in the
presence of either fulvestrant (100 nM) alone, HRGb1
(10 ng/ml) alone, a combination of the two agents or
the appropriate vehicle control. The coverslips were
then washed with PBS and fixed immediately according
to the immunocytochemical assay to be performed. The
Ki-67 assay used in these studies was performed accord-
ing to the protocol previously described [33].
Assessment
Immunostaining for each assay was assessed by two per-
sonnel using a dual viewing attachment to an Olympus
BH-2 light microscope (Southend-on Sea, Essex, UK).
The percentage of cells that stained positive for nuclear
Ki-67 was determined using a minimum evaluation of
2,000 cells/coverslip.
Statistics
For immunocytochemical analysis, comparisons of the
percentage of cells that stained positive for nuclear Ki-
67 were determined using the Mann-Whitney U test for
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ences between control and treatment groups in all four
cell lines were determined by one-way analysis of var-
iance. Direct comparisons between control and treat-
ment effects were assessed using a post hoc t-test with
either the Tamhane test or the Bonferroni adjustment
factor for unequal and equal variances, respectively. Dif-
ferences were considered significant at the P ≤ 0.05
level.
Results
Anti-ER activity of fulvestrant in four ER-positive breast
cancer cell lines
Western blot analysis revealed that treatment of MCF-7,
T47D, BT474 and MDAMB361 cell lines with fulves-
trant at a concentration of 100 nM for seven days
resulted in a substantial reduction in ERa protein levels
in all four cell lines. The reduction was most apparent
in MCF-7 and T47D cells, withe x p r e s s i o no fE Rb e i n g
virtually abolished; however, ERa expression was still
clearly apparent, although greatly reduced, in fulves-
trant-treated BT474 and MDAMB361 cells (Figure 1A).
Loss of ERa expression in response to fulvestrant treat-
ment was associated with reductions in PgR mRNA and
cyclin D1 protein expression in all four cell lines, indica-
tive of a reduction in ERa transcriptional activity (Figure
1B). Cell proliferation was also significantly reduced by
fulvestrant treatment in a concentration-dependent
manner in all four cell lines with this pure anti-ER, with
the maximal concentration being 100 nM, significantly
reducing growth by about 90% in MCF-7 cells and
approximately 80% in MDAMB361 cells (P < 0.001, n =
3 for both cell lines) (Figure 1C) and by about 60% in
T47D cells and approximately 50% in BT474 cells (P <
0.01, n = 3 for both cell lines) (Figure 1C). These
decreases in cell numbers were mirrored by similar
reductions in nuclear Ki-67 immunostaining across the
four cell lines, with 100 nM fulvestrant significantly low-
ering nuclear Ki-67 positivity, expressed as mean ± SD,
from 97 ± 1.2% to 55 ± 4.5% in MCF-7 cells (P <0 . 0 1 ,
n = 3), 80 ± 2.2% to 41 ± 3.6% in T47D cells (P < 0.001,
n = 3), 38 ± 2.2% to 13 ± 1.3% in BT474 cells (P <
0.001, n = 3) and 82 ± 0.9% to 38 ± 1.8% in
MDAMB361 cells (P < 0.001, n = 3) (Table 1 and Addi-
tional file 1, Supplementary Figure S1).
Induction of ErbB3 and ErbB4 receptor expression and
signalling by fulvestrant
Expression of ErbB3 protein was observed across the
panel of cell lines; however, ErbB4 protein was detected
only in the T47D, BT474 and MDAMB361 cell lines
(Figure 2A). The expression profile for both ErbB recep-
tors was highly heterogeneous across the four cell lines.
In the ErbB2 low-expressing MCF-7 and T47D cell
lines, seven-day fulvestrant treatment at a concentration
of 100 nM promoted ErbB3 protein but not mRNA
expression in both cell lines (Figures 2B and 2C). ErbB4
mRNA and protein expression increased in response to
fulvestrant in MCF-7 cells; however, in T47D cells,
ErbB4 mRNA and protein expression were clearly
reduced in response to treatment with this pure anti-ER
(Figures 2B and 2C). In the ErbB2-positive BT474 and
MDAMB361 cell lines, ErbB3 mRNA and protein
expression appeared unchanged following treatment
with fulvestrant, whilst ErbB4 protein but not mRNA
expression was clearly enhanced in response to this anti-
hormone (Figures 2B and 2C).
In addition to promoting ErbB3 and ErbB4 receptor
protein expression, fulvestrant treatment also enhanced
basal phosphorylation of both ErbB receptor family
members in all four cell lines (Figure 2C). Two ErbB4
tyrosine (Y) phosphorylation sites, Y1284 and Y1056,
were examined, with increased levels of Y1284 phos-
phorylation seen across all four cell lines following ful-
vestrant treatment and increased Y1056 phosphorylation
being observed in the ErbB2 low-expressing but not in
the ErbB2-overexpressing cell lines in response to the
antihormone (Figure 2C). This enhanced basal ErbB3
and ErbB4 activity was also associated with increased
basal phosphorylation of ERK1/2 in the four cell lines,
with the antihormone having no effect on total ERK1/2
expression (Figure 2C). A differential effect of fulves-
trant on AKT activity was observed in the ErbB2 low-
expressing compared to ErbB2-overexpressing cell lines,
with fulvestrant promoting basal AKT phosphorylation
in MCF-7 and T47D cells but causing, if anything, a
small reduction in phosphorylation of this signalling ele-
ment in the BT474 and MDAMB361 cell lines (Figure
2C).
Fulvestrant sensitises ER-positive cell lines to HRb1
Effect of HRGb1 in the absence of fulvestrant
In the MCF-7 and T47D cell lines, HRGb1i n d u c e da
concentration-dependent activation of ErbB receptors
and associated downstream signalling elements, with
phosphorylation of both ErbB3, ErbB4, ERK1/2 and
AKT clearly apparent following exposure to 1 to 10 ng/
ml HRGb1 (Figure 3A). Interestingly, HRGb1p h o s -
phorylated ErbB4 predominantly at Y1056 in these cells,
with little effect on Y1284 being observed (data not
shown). Activation of these signalling pathways by
HRGb1 was associated with a trend towards increased
proliferation of MCF-7 but not T47D cells (Figure 3B).
Thus, 10 ng/ml HRGb1 caused a 20% to 30% increase
in cell numbers; however, no obvious increase in Ki-67
immunostaining could be observed, as nuclear expres-
sion of this protein in control MCF-7 cells was close to
100% (Figure 3B, Table 1 and Additional file 1, Supple-
mentary Figure S1). No significant change in T47D cell
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Figure 1 Effect of fulvestrant on ER signalling and growth in MCF-7, T47D, BT474 and MDAMB361 cells. Western blotting and reverse
transcriptase-polymerase chain reaction (RT-PCR) analysis demonstrating effect of a seven-day incubation of MCF-7, T47D, BT474 and MDAMB361
cells with either fulvestrant (100 nM) or vehicle control (ethanol) on (A) oestrogen receptor a (ERa) protein and (B) progesterone receptor (PgR)
mRNA, b-actin mRNAand cyclin D1 protein expression. For each cell line, PgR mRNA expression is shown as upper band and b-actin mRNA as
lower band on RT-PCR image. Data are representative of at least three separate experiments. b-actin protein expression was also assessed for all
Western blotting studies (data not shown) to confirm equivalent sample loading. (C) Effects of increasing concentrations of fulvestrant (0.01 to 1
μM) on the basal growth of MCF-7, T47D, BT474 and MDAMB361 cells on day 7 after initial treatment. The results are expressed as means ± SEM
of triplicate wells and are representative of three separate experiments. *P < 0.05 versus control (0), **P < 0.01 versus control (0), ***P < 0.001
versus control (0).
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however, a small but significant reduction in nuclear Ki-
67 staining from 80% to 63% was noted in response to
this ligand (P <0 . 0 5 ,n =3 )( F i g u r e3 B ,T a b l e1a n d
Additional file 1, Supplementary Figure S1).
In the MDAMB361 and BT474 cell lines, HRGb1
similarly promoted a concentration-dependent activation
of ErbB3, ErbB4, AKT and ERK1/2 (Figure 4A); how-
ever, in these cell lines, HRGb1 phosphorylated ErbB4
primarily on Y1284 (Figure 4A), with little phosphory-
lated Y1056 observed (data not shown). BT474 cells
appeared less responsive than MDAMB361 cells to
HRGb1 with respect to activation of AKT and ERK1/2,
with increased activity of both these elements being
seen only in response to the highest concentration of
this ligand (10 ng/ml). Interestingly, activation of these
signalling pathways had diametrically opposite effects on
proliferation of the two cell lines. Thus, HRGb1w a sa
modest growth suppressor of MDAMB361 cells, with a
10 ng/ml concentration significantly decreasing cell
number by about 20% (P < 0.01, n = 3) and significantly
reducing Ki-67 staining, expressed as mean ± SD, from
82 ± 0.9% to 59 ± 2.2% (P <0 . 0 0 1 ,n = 3), but a growth
promoter of BT474 cells with cell number significantly
increasing by approximately 20% (P <0 . 0 5 ,n =3 )a n d
nuclear Ki-67 positivity rising significantly from 38 ±
2.2% to 48 ± 2.2% in response to 10 ng/ml HRGb1( P<
0.001, n = 3) (Figure 4B, Table 1 and Additional file 1,
Supplementary Figure S1).
Effects of HRGb1 in the presence of fulvestrant
Following a seven-day treatment with fulvestrant, the
MCF-7 and T47D cell lines demonstrated enhanced sen-
sitivity to increasing concentrations of HRGb1, with
phosphorylation of ErbB receptors ERK1/2 and AKT
observed at the lower concentration of 0.1 ng/ml
HRGb1a n dag r e a t e rm a g n i t u d eo fp h o s p h o r y l a t i o n
apparent in response to the higher concentrations of the
ligand (Figures 3A). This enhanced signalling response
to HRGb1 was associated with recovery of cyclin D1
protein expression and enhanced proliferative activity
with HRGb1 treatment completely overriding the
growth-inhibitory effects of fulvestrant in both cell lines
(P < 0.001, n = 3) (Figures 3B and 3C). Indeed, fulves-
trant treatment converted HRGb1f r o mal i g a n dw i t h
limited or negligible proliferative activity to one that
potently and significantly promoted cell growth in both
cell lines (P < 0.001, n = 3) (Figure 5A). This was clearly
reflected in the Ki-67 immunostaining of MCF-7 cells,
with HRGb1 increasing nuclear Ki-67 positivity scores,
expressed as mean ± SD, from 55 ± 4.5% to 89 ± 1.8%
in MCF-7 cells (P < 0.01, n =3 ) ;h o w e v e r ,i nT 4 7 D
cells, although an increase from 41 ± 3.6% to 49 ± 5.8%
was observed in response to HRGb1 in the presence of
fulvestrant, it did not reach statistical significance (Table
1 and Additional file 1, Supplementary Figure S1).
Enhanced sensitivity and an increased magnitude of
response to HRGb1 was also observed in MDAMB361
and BT474 cells following fulvestrant exposure, with
enhanced phosphorylation levels of ErbB4 and ERK1/2
being observed in both cell lines in response to increas-
i n gc o n c e n t r a t i o n so ft h i sl i g a n d( F i g u r e4 A ) .H R G b1-
induced activation of ERK1/2 was less apparent in
BT474 cells compared to MDAMB361 cells, but a small
increase in ERK1/2 activity in response to the lower
concentrations of the ligand, particularly 0.1 ng/ml, was
still apparent in the BT474 cell line, indicative of a sen-
sitisation effect of fulvestrant in these cells. Enhanced
HRGb1-induced ErbB3 phosphorylation was also seen in
the MDAMB361 cells but not the BT474 cells in the
presence of fulvestrant (Figure 4A). Interestingly, in
both cell lines, there was no sensitisation of AKT activ-
ity in response to HRGb1; if anything, there appeared to
be a reduced response to the lower concentrations of
this ligand (0.1 to 1 ng/ml) following fulvestrant treat-
ment, which was most apparent in the BT474 cell line
(Figure 4A). As a consequence of the enhanced HRGb1-
induced signalling seen in both cell lines in the presence
of fulvestrant, once again, this ligand was able to pro-
mote recovery of cyclin D1 protein expression and
potently and significantly overcome the growth-inhibi-
tory effects of the antihormone in both cell lines (P <
0.001, n = 3) (Figures 4B and 4C). Furthermore, as
observed in the ErbB2 low-expressing cell lines, fulves-
trant treatment significantly enhanced the proliferative
Table 1 Effects of fulvestrant, HRGb1 or a combination of the two treatments on immunocytochemically determined
nuclear Ki-67 positivity in MCF-7, T47D, BT474 and MDAMB361 cells
Nuclear Ki-67 positivity, %
Cell type Control Fulvestrant HRGb1 Fulvestrant + HRGb1
MCF-7 97 ± 1.2 55 ± 4.5* 90 ± 0.4 89 ± 1.8†
T47D 80 ± 2.2 41 ± 3.6* 63 ± 2.7** 49 ± 5.8
BT474 38 ± 2.2 13 ± 1.3* 48 ± 2.2*** 50 ± 1.3††
MDAMB361 82 ± 0.9 38 ± 1.8* 59 ± 2.2** 71 ± 2.2††
HRGb1, heregulin b1. Nuclear positivity percentage values are expressed as means ± standard deviation of the assessment of six fields of view per coverslip in
triplicate experiments.
*P < 0.001 versus control, **P < 0.05 versus control, ***P < 0.01 versus control,
†P < 0.01 versus fulvestrant,
††P < 0.001 versus fulvestrant.
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ligand from one that suppressed growth into one that
potently and significantly promoted MDAMB361 cell
growth (P < 0.001, n = 3) (Figure 5A). This ability of
HRGb1 to promote growth in both cell lines in the pre-
sence of fulvestrant was again reflected in Ki-67 immu-
nostaining, with nuclear Ki-67 positivity, expressed as
mean ± SD, significantly rising from 13 ± 1.3% to 50 ±
1.3% in BT474 cells and from 38 ± 1.8% to 71 ± 2.2% in
MDAMB361 cells in the presence of a 10 ng/ml concen-
tration of this ligand (P <0 . 0 0 1 ,n = 3 for both cell lines)
(Table 1 and Additional file 1, Supplementary Figure S1).
Effects of HRGb1 in the presence of fulvestrant in
combination with either gefitinib or herceptin
Treatment of MCF-7 cells with a combination of fulves-
trant and either gefitinib (1 µM) or herceptin (100 nM)
for seven days significantly and potently reduced cell
growth (P < 0.001, n = 3). Although this result was not
statistically significant, there was a trend towards the
combination’s providing a greater inhibition of cell
growth compared to fulvestrant alone. However, this
enhanced growth-inhibitory action of the combination
treatments did not achieve statistical significance com-
pared with the fulvestrant-alone arm (Figure 5B). Impor-
tantly, HRGb1 treatment was capable of a partial but
statistically significant increase in cell growth in the pre-
sence of both fulvestrant and herceptin (P < 0.01, n =3 )
and fulvestrant and gefitinib (P <0 . 0 1 ,n = 3) combina-
tion therapies in this cell line (Figure 5B).
Discussion
Antihormonal therapy has proved to be highly success-
ful in the treatment of ER-positive breast cancer; how-
ever, resistance to these agents remains a significant
clinical problem, with many patients either gaining no
benefit or relapsing during therapy [15]. Numerous pre-
clinical and clinical studies have established that
increased expression of two members of the ErbB recep-
tor family, EGFR and ErbB2, plays a central role in the
acquisition of resistance to antihormonal therapies
[12-19]. Upregulation of EGFR and ErbB2 has been
reported to be an early response to antihormone treat-
ment in ER-positive breast cancer cell lines [2-4,6-11];
however, despite a number of preclinical findings
reporting improved magnitude and duration of response
with combined targeting of EGFR/ErbB2 and ER signal-
ling [21], translation of these findings into the clinical
setting has proved largely disappointing, with a large
number of patients gaining little or no benefit from
such combination therapies [20]. Further studies have
now revealed an array of candidate genes with potential
involvement in antihormone resistance, including the
other members of the ErbB receptor family, ErbB3 and
ErbB4. As both ErbB3 and ErbB4 have been identified
as oestrogen-suppressed and antihormone-induced
genes in MCF-7 breast cancer cells [22], we have exam-
ined whether upregulation of these receptors is an early
response to the pure anti-ER fulvestrant in a panel of
four ER-positive breast cancer cell lines, two HER2-
overexpressing and two HER2 low-expressing, and if so,
what effect ligand activation of these receptors has on
the acute growth-inhibitory activity of this antihormone.
Fulvestrant consistently inhibited growth of all four
ER-positive cell lines at day 7 post-antihormone treat-
ment, with MCF-7 and MDAMB361 cells demonstrating
a greater sensitivity than T47D and BT474 cells to this
pure anti-ER. In all four cell lines, the blockade of
growth was associated with substantial reductions in ER
protein expression with resultant decreased transcrip-
tional activity, as evidenced by decreased PgR mRNA
and cyclin D1 protein expression levels. These findings
clearly indicate the potent anti-ER activity of fulvestrant
and are consistent with previous reports of fulvestrant
action in ER-positive breast cancer cell lines [34-36].
However, alongside this potent acute growth-inhibitory
activity of fulvestrant, there was also clear evidence of
the inductive capacity of this agent, with increased
expression of ErbB3 protein expression in the MCF-7
and T47D cells and ErbB4 protein expression in MCF-7,
BT474 and MDAMB361 cell lines at day 7 post-antihor-
mone treatment. Although ErbB3 and ErbB4 have pre-
viously been reported to be ER-suppressed,
antihormone-induced genes in MCF-7 cells [22], we
believe that the present article is the first to report
acute induction of these receptors at the protein level by
antihormonal therapy in a panel of HER2 low-expres-
sing and overexpressing ER-positive breast cancer cell
lines. Interestingly, there was no consistent upregulation
of either the ErbB3 or ErbB4 receptor across the panel
of cell lines; however, increased ErbB3 expression was
common to the ErbB2 low-expressing cells, whilst
enhanced ErbB4 levels were common to the two ErbB2-
overexpressing cell lines. In the T47D cell line, a reduc-
tion in ErbB4 mRNA and protein expression was
observed following fulvestrant treatment, consistent with
previous reports that ErbB4 is an ER-induced and, by
implication, antihormone-suppressed gene in this cell
line [23]. It is also important to note that the increase in
ErbB3 protein expression in MCF-7 and T47D cells and
t h ei n c r e a s ei nE r b B 4p r o t e i ne x p r e s s i o ni nB T 4 7 4a n d
MDAMB361 cells in response to fulvestrant were not
mirrored by any substantial changes in mRNA expres-
sion of these receptors, findings that are fully supported
by Affymetrix gene array analysis of the expression of
these ErbB receptors in the four cell lines prior to and
following 10-day fulvestrant treatment (data not shown).
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fulvestrant is mediated predominantly by a posttran-
scriptional, posttranslational mechanism.
Although research into the role of ErbB receptor sig-
nalling in breast cancer has focused primarily on EGFR
and ErbB2, it is becoming increasingly clear that both
ErbB3 and ErbB4 also have important roles to play in
this disease. ErbB3 has been identified as a key partner
for ErbB2, with this receptor heterodimer being identi-
fied as an oncogenic unit in breast cancer cells [37],
whilst overexpression of ErbB4 has also been shown to
promote growth of human breast cancer cells [38,39].
Furthermore, blockade of ErbB3 expression using an
artificial transcription factor, E3, inhibits breast cancer
cell growth and targeted downregulation of ErbB4, using
either ribozymes or small interfering RNA, can reduce
the growth of MCF-7 and T47D cell lines both in vitro
and in vivo [23,40]. Both receptors have also been
shown to be overexpressed in breast cancer; however,
their prognostic significance remains a subject of debate.
High expression of ErbB3 has been shown to have a
positive association with tumour size, recurrence, metas-
tasis and significantly reduced patient survival [41-46].
However, ErbB3 receptor status has also been reported
to have a positive prognostic value by associating with
an ER-positive phenotype and longer disease-free survi-
val for breast cancer patients [45,47,48]. Similarly, an
association between the expression of ErbB4 and a
favourable clinical outcome has been reported in some
clinical studies [41,45,48,49], whilst other researchers
have suggested that ErbB4 expression might be a marker
of a poorer outcome in some breast cancer patients
[43,50]. These discrepancies are probably due to the fact
that the function of these receptors is highly reliant on
their localisation and the relative expression levels of
other ErbB receptor family members within the tumour
cells. For example, both ErbB3 and ErbB4 have been
found to localise not only at the membrane but also
within the nucleus in breast cancer cells [51,52]. The
role of nuclear ErbB3 remains unclear; however, levels
are higher in nonmalignant versus malignant breast
epithelial cells, suggesting that it may have potential
antiproliferative activity [51]. In contrast, ErbB3 localised
at the membrane can heterodimerize with other ErbB
family members, principally ErbB2, in response to ligand
stimulation to potently promote breast cancer cell
growth [37]. In the case of ErbB4, nuclear expression of
the intracellular domain of this receptor generated by
the proteolytic actions of tumour necrosis factor-a-con-
verting enzyme and g-secretase following ligand binding
promotes ER-driven cell growth [23,52], whilst cytosolic
and membrane localisation of ErbB4 has been shown to
inhibit growth and promote apoptosis in breast cancer
cells [53-55]. This varied function according to ErbB
receptor expression and localisation may also go some
way toward explaining the differential effect of HRGb1
on the growth of the four breast cancer cell lines we
observed in the present study. In MCF-7 and BT474
cells, HRGb1 promoted cell growth, whilst this ligand
had little effect on T47D cell proliferation and actually
suppressed growth of MDAMB361 cells. A possible
explanation for this is that the antiproliferative activity
of ErbB4 may be more prominent in the T47D and
MDAMB361 cell lines, as HRGb1-induced activation of
this receptor relative to ErbB3 was far greater in these
cells compared to the other two cell lines.
In addition to enhancing total protein expression
levels, fulvestrant treatment also promoted basal ErbB3
and ErbB4 phosphorylation in all four cell lines, which
indicates enhanced signalling through these ErbB recep-
tors. Indeed, the enhanced level of ErbB3 and ErbB4
phosphorylation in the MCF-7 and T47D cell lines was
associated with increased activation of both the MAPK/
ERK1/2 and PI3K/AKT signalling pathways, whilst in
the BT474 and MDAMB361 cell lines, it was associated
with increased ERK1/2 but not AKT activity, possibly
reflecting the continued dominant role of ErbB2, a key
recruiter of the MAPK pathway, in these cells. This
induction of ErbB3 and ErbB4 signalling by fulvestrant,
as previously suggested for EGFR and ErbB2, may pro-
vide these cells with a further input into signalling path-
ways that could potentially allow cells to survive the
initial action of the antihormone and ultimately provide
a resistance mechanism [5]. Indeed, this is supported by
our finding that fulvestrant treatment enhanced the abil-
ity of HRGb1 to stimulate signalling via ErbB3 and
ErbB4, resulting in this ligand’s potently overriding the
suppression of cyclin D1 protein expression and the
blockade of growth by fulvestrant in all four cell lines.
Importantly, following fulvestrant treatment, HRGb1
was converted from a ligand having quite differential
effects on cell growth into one that consistently and
potently promoted proliferation in all four cell lines
examined. Interestingly, the mechanisms by which
HRGb1o v e r c a m ef u l v e s t r a n ta c t i o nw e r es u b t l yd i f f e r -
ent in the HER2 low-expressing and HER2-overexpres-
sing cell lines. In the MCF-7 and T47D cells, fulvestrant
selectively enhanced the ability of HRGb1 to phosphory-
late ErbB4 at Y1056, a PI3K-p85 recruitment site [56],
and promote AKT signalling activity, whereas in the
BT474 and MDAMB361 cells, it was the HRGb1-
induced ErbB4 Y1284 SHC recruitment site [56] and
ERK1/2 phosphorylation that were selectively augmen-
ted by antihormonal treatment. The differential ErbB4
phosphorylation and downstream pathway recruitment
may reflect the expression of alternative ErbB4 isoforms
in these cells, with the CYT-2 isoform, which lacks the
Y1056 PI3K binding consensus site, potentially being
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lines [57]. It is also possible that such differences may
arise from distinct heterodimerization partners binding
ErbB4 in response to HRGb1i nt h eE r b B 2l o w - e x p r e s -
sing and ErbB2-overexpressing cell lines following ful-
vestrant treatment. Researchers in ongoing studies are
currently examining these possibilities. In MCF-7 cells,
it seems that the likely heterodimerization partner for
ErbB4 is ErbB3, as blockade of either EGFR with gefiti-
nib or ErbB2 with herceptinw a sw i t h o u te f f e c to nt h e
ability of HRGb1 to promote cell growth. Importantly,
these findings also indicate that HRGb1 signalling via
ErbB3 and ErbB4 can provide a potent mechanism of
resistance to such combination therapies and may provide
an explanation for the disappointing results of clinical stu-
dies in which the combination strategy of antihormones
alongside an anti-EGFR or anti-ErbB2 agent was examined
[20,21]. These findings are identical to those of Sonne-
Hansen and colleagues [58], who demonstrated that
HRGb1 can override the growth-inhibitory effects of ful-
vestrant in combination with cetuximab, trastuzumab or
pertuzumab in MCF-7 cells. This group also showed that
combining fulvestrant with a pan-ErbB inhibitor effectively
prevented HRGb1-induced growth in this cell line, further
emphasising the key findings of the present study: that
ErbB3 and ErbB4 have the potential to play a central role
in the development of resistance to this antihormonal
therapy [58]. However, it should also be noted that all of
these studies were performed in a single cell line and that
further studies in the other ER-positive cell lines are
required to fully support this proposition.
Conclusions
These current findings demonstrate that targeting ER
signalling with the pure anti-ER fulvestrant can both
suppress and induce gene and protein expression in ER-
positive, ErbB2 low-expressing and ErbB2-overexpres-
sing breast cancer cell lines. As expected, fulvestrant
was a potent growth inhibitor in all four of these ER-
positive breast cancer cell lines through its ability to
suppress proliferation-related genes such as cyclin D1.
However, the simultaneous induction of ErbB3 and
ErbB4 also provided a mechanism for these cells, when
in a HRGb1-enriched environment, to promote reex-
pression of cyclin D1 and ultimately drive fulvestrant-
resistant cell growth. What is more, fulvestrant treat-
ment converted HRGb1 from a ligand with both
growth-promoting and growth-suppressive activity,
depending on cell type, into one that consistently and
potently promoted cell growth, regardless of ErbB2 sta-
tus. Thus, although antihorm o n e ss u c ha sf u l v e s t r a n t
may have potent, acute growth-inhibitory activity in ER-
positive breast cancer cells, their ability to rapidly
induce and sensitize cells to growth factors such as
HRGs may serve to reduce and ultimately limit their
inhibitory activity. Indeed, such a rapid induction of
these proliferative genes may provide a mechanism of
de novo endocrine resistance in situations in which
H R Ge x p r e s s i o ni nt h et u m o u rm i c r o e n v i r o n m e n ti s
high.
Additional material
Additional file 1: Supplementary Figure S1. Effect of HRGb1 (10 ng/
ml) on nuclear Ki-67 immunostaining in MCF-7, T47D, BT474 and
MDAMB361 cells maintained for 7 days in the presence of either
fulvestrant (100 nM) or vehicle control (ethanol).
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